294 related articles for article (PubMed ID: 11448932)
1. In vivo antitumor activity of bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(IV) (METVAN [VO(SO4)(Me2-Phen)2]).
Narla RK; Chen CL; Dong Y; Uckun FM
Clin Cancer Res; 2001 Jul; 7(7):2124-33. PubMed ID: 11448932
[TBL] [Abstract][Full Text] [Related]
2. Bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(IV) as a novel apoptosis-inducing anticancer agent.
Narla RK; Dong Y; D'Cruz OJ; Navara C; Uckun FM
Clin Cancer Res; 2000 Apr; 6(4):1546-56. PubMed ID: 10778988
[TBL] [Abstract][Full Text] [Related]
3. Metvan: a novel oxovanadium(IV) complex with broad spectrum anticancer activity.
D'Cruz OJ; Uckun FM
Expert Opin Investig Drugs; 2002 Dec; 11(12):1829-36. PubMed ID: 12457442
[TBL] [Abstract][Full Text] [Related]
4. In vivo toxicity, pharmacokinetics, and anticancer activity of Genistein linked to recombinant human epidermal growth factor.
Uckun FM; Narla RK; Zeren T; Yanishevski Y; Myers DE; Waurzyniak B; Ek O; Schneider E; Messinger Y; Chelstrom LM; Gunther R; Evans W
Clin Cancer Res; 1998 May; 4(5):1125-34. PubMed ID: 9607569
[TBL] [Abstract][Full Text] [Related]
5. Bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(I.V.) as a novel antileukemic agent with matrix metalloproteinase inhibitory activity.
Narla RK; Dong Y; Klis D; Uckun FM
Clin Cancer Res; 2001 Apr; 7(4):1094-101. PubMed ID: 11309362
[TBL] [Abstract][Full Text] [Related]
6. 4-(3'-Bromo-4'hydroxylphenyl)-amino-6,7-dimethoxyquinazoline: a novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells.
Narla RK; Liu XP; Myers DE; Uckun FM
Clin Cancer Res; 1998 Jun; 4(6):1405-14. PubMed ID: 9626456
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
8. Preclinical antitumor activity, pharmacokinetics and pharmacodynamics of imexon in mice.
Pourpak A; Meyers RO; Samulitis BK; Sherry Chow HH; Kepler CY; Raymond MA; Hersh E; Dorr RT
Anticancer Drugs; 2006 Nov; 17(10):1179-84. PubMed ID: 17075317
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
10. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
11. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents.
Studeny M; Marini FC; Dembinski JL; Zompetta C; Cabreira-Hansen M; Bekele BN; Champlin RE; Andreeff M
J Natl Cancer Inst; 2004 Nov; 96(21):1593-603. PubMed ID: 15523088
[TBL] [Abstract][Full Text] [Related]
12. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme.
Phuong LK; Allen C; Peng KW; Giannini C; Greiner S; TenEyck CJ; Mishra PK; Macura SI; Russell SJ; Galanis EC
Cancer Res; 2003 May; 63(10):2462-9. PubMed ID: 12750267
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
Man S; Bocci G; Francia G; Green SK; Jothy S; Hanahan D; Bohlen P; Hicklin DJ; Bergers G; Kerbel RS
Cancer Res; 2002 May; 62(10):2731-5. PubMed ID: 12019144
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
Chen P; Cameron R; Wang J; Vallis KA; Reilly RM
J Nucl Med; 2003 Sep; 44(9):1469-78. PubMed ID: 12960194
[TBL] [Abstract][Full Text] [Related]
15. Species differences in troxacitabine pharmacokinetics and pharmacodynamics: implications for clinical development.
Gourdeau H; Leblond L; Hamelin B; Dong K; Ouellet F; Boudreau C; Custeau D; Richard A; Gilbert MJ; Jolivet J
Clin Cancer Res; 2004 Nov; 10(22):7692-702. PubMed ID: 15570003
[TBL] [Abstract][Full Text] [Related]
16. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
Hernandez-Ilizaliturri FJ; Jupudy V; Ostberg J; Oflazoglu E; Huberman A; Repasky E; Czuczman MS
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5866-73. PubMed ID: 14676108
[TBL] [Abstract][Full Text] [Related]
17. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin.
Int J Toxicol; 2007; 26 Suppl 1():3-106. PubMed ID: 17365137
[TBL] [Abstract][Full Text] [Related]
18. Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.
Leggas M; Stewart CF; Woo MH; Fouladi M; Cheshire PJ; Peterson JK; Friedman HS; Billups C; Houghton PJ
Clin Cancer Res; 2002 Sep; 8(9):3000-7. PubMed ID: 12231547
[TBL] [Abstract][Full Text] [Related]
19. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
20. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340.
Price A; Shi Q; Morris D; Wilcox ME; Brasher PM; Rewcastle NB; Shalinsky D; Zou H; Appelt K; Johnston RN; Yong VW; Edwards D; Forsyth P
Clin Cancer Res; 1999 Apr; 5(4):845-54. PubMed ID: 10213221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
